Objectives: To examine the prevalence of multidrug-resistant (MDR) urinary Escherichia coli among US outpatients and to assess the antimicrobial activity of oral antibiotics commonly used to treat urinary tract infections (UTIs) against MDR isolates.
Introduction
Urinary tract infections (UTIs) result in 8000 000 physician visits per year in the USA and remain one of the most common indications for prescribing an antibiotic. 1 The causative pathogen in 75%-95% of cases is Escherichia coli, and the majority of these infections occur among outpatients. 2 Prescribing practices for the outpatient treatment of UTIs vary greatly.
3 Although guidelines from the Infectious Diseases Society of America (IDSA) recommend nitrofurantoin and trimethoprim/sulfamethoxazole as first-line empirical treatment for acute uncomplicated cystitis in women, 4 broad-spectrum agents such as fluoroquinolones are frequently prescribed. 5 This inappropriate prescribing is driven in part by concern for multidrug-resistant (MDR) infections, which have been associated with poor clinical outcomes, lower cure rates and increases in patient morbidity and mortality. 6 Several studies have noted the proliferation of MDR E. coli in the USA, but few have examined the antimicrobial activity of nitrofurantoin against MDR isolates. 6 -9 The objectives of this study were to analyse antimicrobial susceptibility test (AST) data in a national surveillance system to describe the prevalence of urinary MDR E. coli among US outpatients and to assess the antimicrobial activity of oral antibiotics commonly used to treat UTIs against MDR isolates.
Methods
We queried The Surveillance Network (TSN) Database USA (Eurofins Medinet, Chantilly, VA, USA) to select AST results from outpatient urinary E. coli isolates tested in 2001 and 2010. Six antimicrobial agents from six separate drug classes were analysed: ampicillin, cefalotin, ciprofloxacin, nitrofurantoin, trimethoprim/sulfamethoxazole and amoxicillin/clavulanate. Although cefalotin is an intravenous agent, it was selected as a 10 In short, TSN collects AST data from .200 institutions in the USA using FDA-approved testing methods and interprets these data using CLSIrecommended breakpoint criteria. TSN has been used previously to evaluate trends in antimicrobial resistance.
11
Multidrug resistance was defined as resistance to three or more of the tested antimicrobial agents. Intermediate results were not counted as resistant. Isolates were categorized as resistant to one, two, three, four, five and six agents and compared for the years 2001 and 2010. Phenotypes of MDR isolates were assessed to determine antimicrobial activity of IDSA-recommended therapy for UTIs, which includes nitrofurantoin, trimethoprim/sulfamethoxazole and ciprofloxacin. A x 2 test using SAS version 9.2 (SAS Institute, Cary, NC, USA) was used to determine whether differences between 2001 and 2010 were statistically significant. The a level for statistical significance was set at 0.05. (Table 1 ). In 2010, among E. coli that demonstrated resistance to three, four and five agents, resistance to nitrofurantoin was observed in only 2.1%, 7.5% and 24.1% of isolates, respectively. Conversely, widespread resistance was observed for trimethoprim/sulfamethoxazole (62.6%, 88.6% and 97.9% for isolates resistant to three, four and five agents, respectively) and ciprofloxacin (48.9%, 84.3% and 98.2% for isolates resistant to three, four and five agents, respectively). The most common resistance phenotype expressed among MDR E. coli was resistance to ampicillin, cefalotin and trimethoprim/sulfamethoxazole.
In an analysis of isolate resistance to individual antimicrobials, E. coli antimicrobial resistance to all studied agents increased; the increase was pronounced for ciprofloxacin (resistance increased from 38.4% to 43.4% for ampicillin, from 13.5% to 17.2% for cefazolin, from 4.4% to 14.9% for ciprofloxacin, from 1.0% to 1.4% nitrofurantoin, from 18.8% to 25.6% for trimethoprim/sulfamethoxazole and from 3.1% to 5.0% for amoxicillin/clavulanate) ( Table S1 , available as Supplementary data at JAC Online).
Discussion
Our study demonstrates the consistent antimicrobial activity of nitrofurantoin against isolates of MDR urinary E. coli in US outpatients and observed no statistically significant differences in nitrofurantoin activity between non-MDR and MDR isolates.
Clinical practice guidelines suggest fluoroquinolones such as ciprofloxacin should be reserved for higher-acuity infections due to their propensity for collateral damage, such as antibiotic resistance. 4 Despite this, ciprofloxacin remains one of the most frequently prescribed antibiotics for the treatment of outpatient UTIs, indicative of a larger trend of healthcare provider preference for broad-spectrum agents. 5 Recent qualitative research suggests prescribers often use second-line broad-spectrum agents for the treatment of uncomplicated infections due to concerns about inconsistent efficacy of narrow-spectrum targeted therapies during a time of escalating antibiotic resistance and consequent . Despite these concerns, the present study demonstrates that, even among MDR isolates resistant to five out of six of the studied antimicrobial classes, nitrofurantoin has consistent and reliable antimicrobial activity against urinary E. coli, further reinforcing this agent as an ideal empirical treatment option for suspected acute uncomplicated cystitis in outpatients. There were substantial increases in E. coli antimicrobial resistance to ciprofloxacin over our study time period. Increased E. coli fluoroquinolone resistance has been associated with higher resistance to non-fluoroquinolone agents. 9 This is likely a consequence of both the spread of resistant clones and increases in selective pressures promoting resistance, such as more frequent fluoroquinolone prescribing. 12 -14 Clonal groups of E. coli such as ST131 contribute significantly to the spread of multidrug resistance, have been found to be more virulent than other fluoroquinolone-resistant strains 15, 16 and may partially explain the marked increase in MDR observed in our study.
Previously observed increases in outpatient E. coli antimicrobial resistance 11 are reflected in the MDR phenotypes seen in our study, and raise concerns about the widespread incidence of antibiotic resistance in the community. Although trimethoprim/ sulfamethoxazole remains a recommended treatment option for uncomplicated UTIs in communities with low resistance (,20%), 4 our data suggest that E. coli trimethoprim/sulfamethoxazole resistance exceeded 20% in 2010 and is highly prevalent among isolates resistant to at least two agents.
Limitations of the present study include likely underrepresentation of isolates that were treated successfully using empirical treatment, limited clinical data describing the patients from whom urinary isolates were collected and variation in on-site AST methods. Direct comparisons with previous research are difficult due to inconsistent definitions of MDR and inconsistent panels of antimicrobial agents against which isolates were tested. 6 -9 Strengths of our study include a geographically representative distribution of data and a large sample size of urinary isolates.
Although the frequency of urinary MDR E. coli among US outpatients increased between 2001 and 2010, nitrofurantoin demonstrated consistent antimicrobial activity against MDR E. coli. As the prevalence of MDR E. coli increases, nitrofurantoin remains a viable first-line targeted antimicrobial for the empirical treatment of suspected acute uncomplicated cystitis. Nitrofurantoin activity against MDR E. coli
